№ files_lp_3_process_9_66095
File format: docx Character count: 15967 File size: 34 KB
Year: 2026
Region / City: Not specified
Topic: Pediatric Hematology, Neurotoxicity
Document Type: Case Report
Institution: Not specified
Author: Not specified
Target Audience: Medical professionals
Patient Age: 6–14 years
Diagnosis: Relapsed B-cell Acute Lymphoblastic Leukemia (B-ALL)
Treatment Protocols: MRC-11, BFM 2002
Drug: High-Dose Methotrexate (HDMTX), Intrathecal Methotrexate (ITMTX), Levetiracetam, Diazepam
Clinical Events: Generalised tonic-clonic seizures, neurotoxicity
Outcome: Successful continuation of HDMTX and ITMTX without further seizures
Follow-up Duration: 2 years 3 months of anti-convulsant therapy
Imaging Findings: Normal brain MRI, hepatosplenomegaly on abdominal ultrasound
Laboratory Findings: Bone marrow immunophenotyping and cytogenetics detailed in report
Risk Stratification: Intermediate
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Addendum to the November 2024 PBAC Meeting Regarding the Listing of Blinatumomab for the Treatment of MRD-negative B-ALL
Year: 2024
Region / City: Australia
Subject: Blinatumomab, B-ALL, MRD-negative, PBS listing, chemotherapy
Document Type: Addendum
Organization / Institution: PBAC, TGA
Author: PBAC Secretariat
Target Audience: Medical practitioners, healthcare professionals
Validity Period: Not specified
Approval Date: November 2024
Amendment Date: Not specified
HIGH DOSE INACTIVATED TRIVALENT INFLUENZA VACCINE (SPLIT VIRION), Injection 0.5 mL, Fluzone® High-Dose, Sanofi–Aventis Australia Pty Ltd
Year: 2020
Region / city: Australia
Subject: Influenza Vaccination
Document Type: Resubmission for listing
Agency / institution: Pharmaceutical Benefits Advisory Committee (PBAC)
Author: Sanofi-Aventis Australia Pty Ltd
Target Audience: Healthcare providers, public health authorities
Period of validity: From 2020 onward
Approval Date: July 2019
Date of amendments: July 2019
Inactivated trivalent influenza vaccine (Split Virion) suspension for injection, 180mcg single dose in 0.5mL, Fluzone High-Dose, Australia, 2017–2018
Year: 2017
Country: Australia
Vaccine type: Inactivated trivalent influenza vaccine (TIV-HD)
Manufacturer: Sanofi-Aventis Australia Pty Ltd
Product form: Suspension for injection, 180mcg single dose in 0.5mL
Regulatory approval: TGA registration December 2017
Target population: Persons aged 65 years and older
Purpose: Listing on National Immunisation Program (NIP)
Comparative analysis: Cost-minimisation versus standard quadrivalent influenza vaccine (QIV)
Advisory review: PBAC and ATAGI evaluation
Implementation considerations: Cold chain capacity, provider communication, monitoring adverse events
Topics: Methotrexate-Induced B-ALL High-Dose